Kornimate/medical-research-clean huggingface dataset:
maternal vitamin d levels in pregnancy and dental caries in children

Conditions: Vitamin D Deficiency; Dental Caries; Dental Enamel Hypoplasia

Summary: the main aim of this study is to investigate potential associations between maternal pre- and postnatal vitamin d level and oral health outcomes (caries and developmental defects of enamel) in their children at 7-9 years of age.

vitamin d plays an important part in calcium absorption needed for calcification of hard tissues such as bone. lack of vitamin d can lead to growth retardation in children and a variety of bone related problems in adulthood such as osteopenia, osteoporosis and increased risk of bone fracture. vitamin d deficiency has also been associated with a variety of other health problems. in relation to oral health, studies have suggested that lack of vitamin d may interfere with tooth development resulting in development defects of the enamel, which in turn increase the risk of dental caries. as teeth begin to calcify around 14 weeks in utero and continue until the enamel on the last primary tooth is completed around ten months after birth, it is plausible that both pre- and postnatal vitamin d levels can have an impact on the development of the enamel in primary teeth in the offspring, which in turn may be related to the risk of developing enamel defects and dental caries. furthermore, vitamin d may play a role in the immune system and thereby affect the oral microflora. vitamin d could therefore also affect the risk of caries through immunological pathways. few previous studies have investigated the associations between vitamin d and oral health outcomes, such as these. the aim of this study is to investigate the potential associations between maternal pre- and postnatal vitamin d levels and oral health outcomes, such as caries and dental enamel defects in the offspring at 7-9 years of age. the current study is a follow-up study of a previous study conducted in trondheim and stavanger, norway. in 2007-2009 a total of 855 pregnant women participated in the training in pregnancy (trip) study, a randomised controlled trial study conducted to investigate whether exercise during pregnancy would help prevent or treat various pregnancy related illnesses. the women were included between weeks 18-22 of pregnancy and were followed-up at week 32-36 of pregnancy and at 3 months post-partum. an additional follow-up was also conducted among the participants from trondheim at 18 months post-partum. the data collection included both questionnaires, clinical examinations and blood samples. the blood samples taken from the mothers at 18-22 weeks and 32-36 weeks of pregnancy have been analysed for levels of vitamin d, calcium, phosphate, magnesium, creatinine, albumin and pth. in the current study, the children are invited to a dental examination, including a saliva sample. these clinical examinations will be conducted from june 2016 through to august 2017.

Eligibility criteria:
inclusion criteria: * mother of the child participated in the main study "training in pregnancy" exclusion criteria: * consent not given

Keywords: oral health vitamin d
the effect of a weight-loss diet in women doing reformer pilates: a 12-week evaluation

Conditions: Pilates; Diet; Women

Summary: the purpose of this study is to determine the effect of a weight-loss diet on body composition in women who practice reformer pilates for 12 weeks. it compares dietary habits and macro and micronutrient intakes in subjects with and without a weight-loss diet at the start and end of the study.

the effect of a weight-loss diet on body composition in women reformer pilates for 12 weeks was compared in this study. it compares dietary habits and macro and micronutrient intakes in subjects with and without a weight-loss diet at the start and end of the study. a total of 49 women (18 years old) were randomly assigned to one of two groups: control (cg: reformer pilates; n=23) or study (sg: reformer pilates + weight-loss diet; n=26). subjects in both groups did pilates for 45 minutes three times a week for a total of 12 weeks. at the start and end of the study, their body weight (kg), waist circumference (cm), hip circumference (cm), neck circumference (cm), mid-upper arm circumference (cm), and body composition \[body fat (% ), body water (% ), body muscle (% )\] were all measured. their waist/height ratio and body mass index (kg/m2) were also measured at the start and end of the study. all subjects' dietary habits were questioned, their 24-hour retrospective food consumption was recorded, and their physical activity levels were assessed using the international physical activity questionnaire (short form).

Eligibility criteria:
inclusion criteria: * agree to participate in the study * being in the age range of 18-65 * female * not a regular pilates practitioner, and physically independent to perform basic daily activities exclusion criteria: * refuse to participate in the study * being younger than 18 or over 65 * male * a regular pilates practitioner * not being suitable for physical activity

Keywords: pilates-based exercises weight loss diet women body composition
stem cell transplant from matched unrelated or partially matched related donors

Conditions: Blood Cancer; Blood and Marrow Transplant (BMT)

Summary: to evaluate the use of unrelated donors for hematopoietic cell transplantation in the treatment of hematologic and lymphoid malignancies.

stem cell transplantation from matched unrelated or partially matched related donors using a preparatory regimen consisting of fractionated total body irradiation (ftbi) and cyclophosphamide (cy). to administer high dose radio-chemotherapy followed by stem cell transplantation from a matched unrelated donor or a partially matched related donor.

Eligibility criteria:
inclusion criteria:- acute leukemia * chronic leukemia * lymphoblastic lymphoma * mds * mps exclusion criteria:- organ dysfunction * hiv positive
pharmacokinetics of idx719 in participants with normal and impaired hepatic function (mk-1894-008)

Conditions: Hepatitis C, Chronic

Summary: the purpose of this study is to evaluate the pharmacokinetics (pk) and safety and tolerability of single-dose administration of idx719 in participants with normal hepatic function and participants with varying degrees of hepatic impairment.


Eligibility criteria:
inclusion criteria: * read and sign the written informed consent form (icf) after the nature of the study has been fully explained. * all subjects of childbearing potential must have agreed to use a double method of birth control (one of which must be a barrier) from screening through at least 90 days after the last dose of the study drug. * male subjects have agreed not to donate sperm from day -1 through 90 days after the last dose of study drug. exclusion criteria: * pregnant or breastfeeding. * other clinically significant medical conditions or laboratory abnormalities

Keywords: chronic hepatitis c hepatitis c virus hcv
a study evaluating implementation strategies for the delivery of cabotegravir in low and high-volume prep site in the united states

Conditions: HIV Infections

Summary: this is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of cabotegravir prep in low and high-volume prep sites in the united states for men who have sex with men (msm) and transgender men ≥ 18 years of age. there are two types of participants in the study. patient study participants (psps) will refer to individuals who are enrolled in the study and who will receive commercially available cabotegravir prep via prescription from the prep provider at the corresponding site. staff study participants (ssps) will refer to site staff who are involved in administrative and clinical aspects of offering and administering prep to psps and will participate in the staff study assessments. psps who choose to opt for 1-month oral lead-in (oli) will receive cabotegravir tablets for prep at month 1 followed by appretude intramuscular (im) injections on month 2, 3 and every two months thereafter up to month 13. psps who opt for direct to injections (dti) will receive appretude im injections on month 1, 2 and every two months thereafter up to month 12. month 6/7 refers to month 6 (dti)/ month 7 (oli). month 12/13 refers to month 12 (dti)/ month 13 (oli).


Eligibility criteria:
inclusion criteria: * participant must be ≥ 18 years of age inclusive, at the time of signing the informed consent. * no prior history of receiving cab prep * hiv negative test result at screening * capable of giving signed informed consent form exclusion criteria: * hiv indeterminate or positive test result during screening and prior to initiation of cab prep * a participant of concurrent interventional clinical or implementation science study at any time during the study

Keywords: cabotegravir long-acting injectables implementation science hiv pre-exposure prophylaxis
paroxysmal nocturnal hemoglobinuria (pnh), level of cd59 on red and white blood cells in bone marrow failure syndromes

Conditions: Hemoglobinuria

Summary: examine red and white blood cells of pnh patients with bone marrow failure syndromes.


Eligibility criteria:
inclusion criteria: * at least 10 years of age. * has aplastic anemia, myelodysplastic syndromes or other bone marrow failure syndromes exclusion criteria: * has any condition that might interfere with the patient's participation

Keywords: pnh clone cells aplastic anemia aa myelodysplastic syndromes mds bone marrow failure syndromes flaer paroxysmal nocturnal hemoglobinuria
efficacy of a low-molecular-weight heparin (bemiparin) in the treatment of chronic foot ulcers in diabetic patients

Conditions: Foot Ulcer, Diabetic; Diabetic Angiopathies

Summary: to assess the efficacy of bemiparin (low molecular weight heparin) for 3 months in the treatment of chronic foot ulcers in diabetic patients.

the involvement of microcirculation in diabetes microangiopathy may be the cause of ulceration and severe incapacitation. torpid ulcers of the lower limbs affect up to 15% of diabetic patients at some moment of their lifetime; about one-third of patients developing ulcers will never achieve their definitive cure, and half of them will die within three years . heparins, besides their well known antithrombotic effects, have been shown to stimulate both the synthesis of heparan sulphate -a potent endogenous anticoagulant- in endothelial cell cultures and the proliferation of fibroblasts taken from diabetic ulcers . after noticing the highly positive evolution of chronic ulcers in six diabetic patients who had received lmwhs in their homes for the prophylaxis of deep vein thrombosis , and considering the excellent safety record of these drugs, we decided to explore the effects of lmwhs on the evolution of diabetic foot ulcers and the quality of life of diabetic patients seen in our primary care practices. comparison: bemiparin vs placebo

Eligibility criteria:
inclusion criteria: * age over 18 years; * type i or ii diabetes mellitus diagnosed (ada 1998) for more than 3 years; * presence of at least one cutaneous ulcer distal to the knee, not involving deep tissues (stages i and ii of wagner's classification ) and existing for at least three months; * giving their written informed consent. exclusion criteria: * hypersensibility to heparin or pig derivatives * body weight lower than 35 kg * presence of clinical signs of infection that did not resolve in spite of oral antibiotics; * anticoagulant therapy; * severe impairment of renal or hepatic function; * bleeding disorder; * active peptic ulcer; * arterial hypertension with poor control; * pregnancy or lactation; * terminal illness or a prognosis of survival under three months.

Keywords: heparin, low-molecular-weight bemiparin foot ulcer, diabetic diabetic angiopathies primary health care
correlation between dental arch and articular eminence

Conditions: Articular Eminence

Summary: the aim of the study is to assess the correlation between the dental arch morphology and the articular eminence height and inclination by using cbct scans of a sample of the egyptian population.


Eligibility criteria:
inclusion criteria: * • cbct scans of adult egyptian patients, males and females with ages starting from 18 till 45. * scans of patients who have complete set of permanent dentitions (third molars are not considered), or at least not more than one tooth is missed in each arch. * cbct scans with field of view that shows the full view of tmj. exclusion criteria: * • cbct scans of patients with fractures in the articular bone surfaces. * cbct scans of patients with pathological lesions in the tmj or articular eminence. * cbct scans with artifacts that could interfere with the assessment of the articular eminence and dental arches.
semaglutide vs dulaglutide on epicardial adipose tissue

Conditions: Epicardial Fat

Summary: epicardial fat (eat), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. eat expresses glp-1 receptors (glp-1r). glp-1 receptor agonist liraglutide is known to significantly decrease eat thickness. however, the effects of glp-1 receptor agonists semaglutide and dulaglutide on eat thickness are unknown

this is a retrospective, observational, case control study. data were obtained from retrospective review of the electronic medical records. patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. each patient underwent routine labs and an onsite ultrasound measurement of eat thickness at baseline and at the routine 12-week follow up visit, as standard of care.

Eligibility criteria:
inclusion criteria: * type 2 diabetes, * bmi ≥27 kg/m2, * age ≥ 18 years old exclusion criteria: * type 1 diabetes * concurrent use of dipeptidyl peptidase 4 (dpp-4) inhibitors or other glp-1 agonist receptors * history of diabetic ketoacidosis * known contraindications to glp-1 receptor agonists such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2 * acute infective diseases, cancer or chemotherapy * use of systemic corticosteroids within the 3 months prior this study * known or suspected allergy to semaglutide or dulaglutide excipients or related products * pregnancy, breastfeeding or the intention of becoming pregnant
a new treatment option for heavy menstrual bleeding

Conditions: Menorrhagia

Summary: women with measured menstrual bleeding \>80ml per cycle and no contraindications to combined oral contraceptive use will be assigned to an oestradiol/nomegestrol acetate oral contraceptive for 3 cycles during which they will collect all menstrual blood and send all used sanitary protection to the laboratory at the university of sydney for estimation of blood loss by the alkaline haematin method. hypothesis: an estradiol/nomogestrel acetate (e2/nomac) combined pill will be effective in controlling hmb in the majority of women without structural pelvic pathology. main outcome: the primary efficacy end-point will be the proportion of women with a reduction of menstrual blood loss ≥ 50% from baseline.

women will collect menstrual blood for 3 cycles and will be eligible to enter the treatment phase if in two of the three pre-treatment cycles the measured menstrual blood loss (mbl)is \>80ml. the mean of these baseline mbl measurements will be the comparator for the efficacy treatment measurement. iron studies (serum ferritin, fe and transferrin) will also be measured pre and post treatment and related to women's assessment of their quality of life measured on a validated questionnaire.

Eligibility criteria:
inclusion criteria: * women aged 18-50 years having regular menstrual cycles * women willing to collect all sanitary protection for 6 cycles * women with no contraindications to use of combined hormonal contraception * women not using any hormonal contraception or any treatment for hmb * women who have no demonstrable uterine pathology on pelvic ultrasound * women who have demonstrated a menstrual blood loss (mbl) \>80mls in 2 of 3 menstrual periods during the pre-treatment phase will be eligible to enter the treatment phase exclusion criteria: * women for whom combined oral contraceptives are contraindicated * women unwilling to collect all sanitary protection for 6 cycles * women using hormonal contraception or any treatment for hmb * women who have demonstrable uterine pathology on pelvic ultrasound * women who have demonstrated a mbl ≤80mls in 2 of 3 consecutive menstrual periods

Keywords: measured heavy menstrual bleeding combined oral contraceptive alkaline haematin method
buddhist understanding and reduction of myanmar experiences of hiv stigma and exclusion

Conditions: Hiv; Stigma, Social; Mindfulness

Summary: this project aims to explore a multi-leveled conceptualization of the effects of hiv stigma on hiv care engagement in myanmar by conducting a mixed-method study.

this project is to explore how myanmar people living with hiv (plwh) experience and manage hiv stigma as inspired by buddhist teaching, and to adapt an evidence-based stigma-reduction intervention to tailor treatment for the unique needs of myanmar people living with hiv. a stigma-reduction intervention will be adopted to the needs of myanmar people living with hiv with six focus groups.

Eligibility criteria:
inclusion criteria: 1. hiv-positive 2. care by myanmar positive group/cmru 3. living in myanmar/thailand 4. can stay in the period of intervention exclusion criteria: 1. not hiv 2. living outside of myanmar/thailand 3. not care by mpg/cmru 4. cannot stay for the study period

Keywords: stigma mindfulness myanmar
laparoscopic sleeve gastrectomy with and without omentectomy

Conditions: Morbid Obesity

Summary: * the investigators aim to determine the clinical and metabolic effects of sleeve gastrectomy with or without omentectomy in the treatment of morbid obesity. * the investigators hypothesize that the endocrine suppression of ghrelin (appetite hormone)and resistin (insulin antagonist) provided by sleeve gastrectomy and omentectomy (omentum or intra-abdominal fat removal) will provide clinical and metabolic benefits for morbidly obese patients.

this is a phase 3 prospective randomized trial.

Eligibility criteria:
inclusion criteria: * morbidly obese veterans only (bmi\>35 with comorbidities or bmi\>40) * age \> 18 exclusion criteria: * pregnancy * uncontrolled medical or psychiatric conditions * previous bariatric procedure

Keywords: morbid obesity bariatric surgery obesity surgery omentectomy sleeve gastrectomy
a double-blinded study to evaluate the safety, tolerability, and efficacy of bms-986020 versus placebo in diffuse cutaneous systemic sclerosis (dcssc)

Conditions: Scleroderma

Summary: this is a two part study. the purpose of part a is to determine if bms-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using one dose of bms-986020. the purpose of part b is to determine if bms-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using two different doses of bms-986020.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * diagnosis of diffuse cutaneous systemic sclerosis for 60 months or less * men and women ≥ 18 years of age * ability to comply with birth control requirements * certain immunosuppressive agents are permitted exclusion criteria: * limited cutaneous systemic sclerosis or sine scleroderma * active ulcers on fingers * pulmonary arterial hypertension * any gastrointestinal surgery that may impact absorption of study drug
cya versus mmf for treatment of moderate-severe psoriasis.

Conditions: Psoriasis

Summary: psoriasis is an immuno-mediated skin disorder, which affects about 2-3% of the population worldwide. for moderate-severe forms of psoriasis systemic immunosuppression is the treatment of choice. this clinical trial was initiated to compare the safety and effectiveness of mycophenolate mofetil and cyclosporine a for the treatment of psoriasis. patients are randomized to receive either 2.5 mg/kg bw cyclosporine a or 1 g bid mycophenolate mofetil. if after six weeks no decrease in the pasi score occures cyclosporine a doses are increased to 5 mg/kg bw for additional six weeks. in the other arm mycophenolate mofetil is increased to 1 g tid for additional six weeks.

not needed.

Eligibility criteria:
inclusion criteria: * moderate-to-severe psoriasis (pasi score equal and greated 10) * written informed consent * for female patients effective birth control exclusion criteria: * psoriasis arthritis * psoriasis palmo-plantaris * erythrodermic psoriasis * drug-induced psoriasis * pregnancy * previous treatment with cyclosporine a or mycophenolate mofetil * pregnancy * reduced liver function * high blood pressure * reduced kidney function * severe viral or bacterial infection * 2 weeks before or after vaccinations * innate or acquired immunodeficiency * severe neurologic or psychiatric symptoms * participation in other trials * other reasons voiced by the treating physician

Keywords: psoriasis randomized clinical trial cyclosporine a mycophenolate mofetil immunosuppression
carboplatin, abraxane, avastin as neoadjuvant therapy for her2-negative breast cancer

Conditions: Breast Cancer

Summary: in the mdacc/bruog neoadjuvant trial with weekly paclitaxel followed by fluorouracil plus doxorubicin and cyclophosphamide (fac), the pathologic complete response (pcr) rate in her2(-) patients was 20%. the investigators' goal is to develop an induction chemotherapy regimen that will have a pcr rate above 30% in patients with her2(-) disease. based on a 1-sided 95% confidence interval using normal approximation with an expected pcr rate of at least 35%, approximately 28 patients are required for each cohort. with an assumed pcr rate of at least 35%, the investigators will have approximately 70% statistical power to conclude, with 90% certainty, that the pcr rate with the novel regimen exceeds 20%. the study will accrue approximately 60 patients in two cohorts with an inevaluable rate that does not exceed 10%.

see above brief summary

Eligibility criteria:
eligibility criteria inclusion criteria: * histologically documented adenocarcinoma of the breast * anc \> 1000 cells * female; age \> 18 * zubrod ps 0-1 * platelets \> 100,000 * stage iia-iiib disease * total bilirubin \< 1.5 uln * no evidence of any metastatic disease * serum creatinine \< 1.5 gm/dl * no prior systemic therapy for breast cancer or creat cl \> 30 ml/min * not pregnant or lactating * serum alt \< 2.0 uln * er, pr and her2 status required * lvef (muga/echo wnl) * no baseline \> 2 neuropathy * urine protein: creat ratio \< 1.0 * her2-negative - either ihc 0-1+ or fish ratio \< 2.0 * hemoglobin \> 9 gm/dl * (fish testing is required for all her2 2-3+ tumors by ihc) exclusion criteria: * no histologically documented adenocarcinoma of the breast * no-anc \> 1000 cells * female; age \< 18 * zubrod ps \> 0-1 * platelets \< 100,000 * stage iv disease * total bilirubin \> 1.5 uln * metastatic disease * serum creatinine \> 1.5 gm/dl * prior systemic therapy for breast cancer or creat cl \> 30 ml/min * pregnant or lactating * serum alt \> 2.0 uln baseline \> 2 neuropathy * urine protein: creat ratio \>1.0 * her2-positive * hemoglobin \< 9 gm/dl

Keywords: breast cancer
study of prn and every 2months intravitreal aflibercept for age related macular degeneration

Conditions: Age-related Macular Degeneration

Summary: evaluate a treatment result of every two months versus as needed (prn) after 3 initial monthly intravitreal aflibercept for the japanese age related macular degeneration.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of age-related macular degeneration exclusion criteria: * any treatment before intravitreal aflibercept for age-related macular degeneration. * visual acuity above 0.1 in decimal visual acuity

Keywords: aflibercept intravitreal injection